Docetaxel

Generic Name: Docetaxel

Brand Names: Taxotere, Docetaxel Accord, Docetaxel Kabi

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₃NO_₁₄

CAS Number: 114977-28-5

Unique Ingredient Identifier: 699121PHCA

Background: Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication: Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer

Associated Therapies: -

Clinical Trials

Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Carboplatin or Cisplatin
Drug: Docetaxel

First Posted Date: 2022-03-31

Last Posted Date: 2023-10-10

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 28

Registration Number: NCT05302011

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Phase 1

Completed

Conditions: Breast Cancer Recurrent
Breast Cancer Metastatic
Breast Cancer Female

Interventions: Drug: Herceptin
Drug: Faceptor
Drug: Docetaxel

First Posted Date: 2022-03-29

Last Posted Date: 2022-03-29

Lead Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company

Target Recruit Count: 50

Registration Number: NCT05301530

Locations: 🇻🇳
19-8 Hospital, Hanoi, Vietnam
🇻🇳
HCMC Oncology Hospital, Ho Chi Minh City, Vietnam

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Phase 3

Completed

Conditions: Breast Cancer Metastatic
Breast Cancer Recurrent
Breast Cancer Female

Interventions: Drug: Faceptor
Drug: Herceptin
Drug: Docetaxel

First Posted Date: 2022-03-29

Last Posted Date: 2023-02-27

Lead Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company

Target Recruit Count: 128

Registration Number: NCT05301010

Locations: 🇻🇳
19-8 Hospital, Hanoi, Vietnam
🇻🇳
HCMC Oncology Hospital, Ho Chi Minh City, Vietnam

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Phase 3

Recruiting

Conditions: Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: Phesgo
Drug: Giredestrant
Drug: Docetaxel
Drug: LHRH Agonist
Drug: Paclitaxel
Drug: Optional Endocrine Therapy of Investigator's Choice

First Posted Date: 2022-03-25

Last Posted Date: 2024-12-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 812

Registration Number: NCT05296798

Locations: 🇮🇹
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy
🇵🇱
Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, Poland
🇵🇹
Hospital de S. Francisco Xavier; Unidade de Oncologia Medica, Lisboa, Portugal

and more 224 locations

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Phase 1

Not yet recruiting

Conditions: Clinical Stage I Gastric Cancer AJCC v8
Clinical Stage II Gastric Cancer AJCC v8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Gastric Adenocarcinoma
Clinical Stage IIA Gastric Cancer AJCC v8
Clinical Stage IIB Gastric Cancer AJCC v8
Pathologic Stage II Gastric Cancer AJCC v8
Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8

Interventions: Drug: Capecitabine
Drug: Docetaxel
Drug: Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Radiation: Radiation Therapy
Procedure: Surgical Procedure

First Posted Date: 2022-03-25

Last Posted Date: 2022-03-25

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT05296005

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Not Applicable

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: doxorubicin
Drug: epirubicin
Drug: pirarubicin
Drug: cyclophosphamide
Drug: albumin-bound paclitaxel
Drug: paclitaxel
Drug: docetaxel

First Posted Date: 2022-03-18

Last Posted Date: 2022-03-31

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 500

Registration Number: NCT05287308

Locations: 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Phase 1

Terminated

Conditions: Squamous-Cell Non-Small-Cell Lung Cancer

Interventions: Drug: Bemarituzumab
Drug: Docetaxel
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Nab-paclitaxel

First Posted Date: 2022-03-04

Last Posted Date: 2024-10-26

Lead Sponsor: Amgen

Target Recruit Count: 74

Registration Number: NCT05267470

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, Taiwan
🇺🇸
Montefiore Einstein Center for Cancer Care, Bronx, New York, United States

and more 36 locations